城市学术医疗中心接受门诊胃肠外抗生素治疗患者的感染发生率较低
Low Incidence of Infection in Patients Receiving Outpatient Parenteral Antibiotic Therapy at an Urban Academic Medical Center.
作者信息
Vo Christopher, Coe Jared, Ahmed Tabeer, Cowman Kelsie, Guo Yi, Nori Priya
机构信息
Division of Infectious Diseases, Department of Medicine, Montefiore Medical Center, Bronx, New York, USA.
出版信息
Open Forum Infect Dis. 2025 May 27;12(6):ofaf314. doi: 10.1093/ofid/ofaf314. eCollection 2025 Jun.
Abstract
Data on infection (CDI) among patients receiving outpatient parenteral antibiotic therapy (OPAT) are limited. Herein, we describe characteristics of OPAT patients with CDI at a large academic medical center. Despite prolonged antibiotic exposure, the incidence rate of CDI was low.
摘要
接受门诊胃肠外抗生素治疗（OPAT）的患者中艰难梭菌感染（CDI）的数据有限。在此，我们描述了一家大型学术医疗中心中发生CDI的OPAT患者的特征。尽管抗生素暴露时间延长，但CDI的发病率较低。
相似文献
1
Low Incidence of Infection in Patients Receiving Outpatient Parenteral Antibiotic Therapy at an Urban Academic Medical Center.城市学术医疗中心接受门诊胃肠外抗生素治疗患者的感染发生率较低
Open Forum Infect Dis. 2025 May 27;12(6):ofaf314. doi: 10.1093/ofid/ofaf314. eCollection 2025 Jun.
2
Real-world use of bezlotoxumab to prevent recurrent infections: a single-center experience and meta-analysis.贝佐妥单抗预防反复感染的真实世界应用：单中心经验及荟萃分析
Therap Adv Gastroenterol. 2025 Jun 21;18:17562848251346593. doi: 10.1177/17562848251346593. eCollection 2025.
3
Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.成人艰难梭菌相关性腹泻的抗生素治疗
Cochrane Database Syst Rev. 2017 Mar 3;3(3):CD004610. doi: 10.1002/14651858.CD004610.pub5.
4
Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).粪便微生物移植治疗复发性艰难梭菌（艰难梭菌）。
Cochrane Database Syst Rev. 2023 Apr 25;4(4):CD013871. doi: 10.1002/14651858.CD013871.pub2.
5
Omadacycline and : A Systematic Review of Preclinical and Clinical Evidence.奥马环素与：临床前和临床证据的系统评价。
Ann Pharmacother. 2023 Feb;57(2):184-192. doi: 10.1177/10600280221089007. Epub 2022 Jun 3.
6
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.用于预防成人和儿童艰难梭菌相关性腹泻的益生菌
Cochrane Database Syst Rev. 2017 Dec 19;12(12):CD006095. doi: 10.1002/14651858.CD006095.pub4.
7
Surveillance and epidemiology of Clostridioides difficile infection using the national health surveillance network criteria: A 7-year study from Mumbai, India.利用国家卫生监测网络标准对艰难梭菌感染进行监测和流行病学研究：来自印度孟买的一项 7 年研究。
Indian J Med Microbiol. 2023 Nov-Dec;46:100425. doi: 10.1016/j.ijmmb.2023.100425. Epub 2023 Jul 12.
8
The emergence of Clostridium difficile infection in Asia: A systematic review and meta-analysis of incidence and impact.亚洲艰难梭菌感染的出现：发病率及影响的系统评价与荟萃分析
PLoS One. 2017 May 2;12(5):e0176797. doi: 10.1371/journal.pone.0176797. eCollection 2017.
9
Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis.及时使用益生菌可预防住院成人艰难梭菌感染：系统评价与荟萃回归分析。
Gastroenterology. 2017 Jun;152(8):1889-1900.e9. doi: 10.1053/j.gastro.2017.02.003. Epub 2017 Feb 10.
10
Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis.胃酸抑制与艰难梭菌反复感染的关联：一项系统评价和荟萃分析。
JAMA Intern Med. 2017 Jun 1;177(6):784-791. doi: 10.1001/jamainternmed.2017.0212.
本文引用的文献
1
Comparison of Different Antibiotics and the Risk for Community-Associated Infection: A Case-Control Study.不同抗生素与社区获得性感染风险的比较：一项病例对照研究
Open Forum Infect Dis. 2023 Aug 5;10(8):ofad413. doi: 10.1093/ofid/ofad413. eCollection 2023 Aug.
2
Clostridium difficile in Immunocompromised Hosts: A Review of Epidemiology, Risk Factors, Treatment, and Prevention.免疫功能低下宿主中的艰难梭菌：流行病学、危险因素、治疗和预防的综述。
Clin Infect Dis. 2019 May 30;68(12):2144-2153. doi: 10.1093/cid/ciy845.
3
Protective Factors in the Intestinal Microbiome Against Clostridium difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.异基因造血干细胞移植受者肠道微生物群中抵抗艰难梭菌感染的保护因素
J Infect Dis. 2017 Apr 1;215(7):1117-1123. doi: 10.1093/infdis/jix011.
4
Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection.兴衰：肠道微生物群对医院暴露和艰难梭菌定植或感染的反应动态。
Microbiome. 2016 Mar 14;4:12. doi: 10.1186/s40168-016-0156-3.
5
Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic C. difficile colonization.艰难梭菌感染和无症状艰难梭菌定植中肠道微生物群变化的见解。
Anaerobe. 2015 Aug;34:1-7. doi: 10.1016/j.anaerobe.2015.03.008. Epub 2015 Mar 26.
6
Burden of Clostridium difficile infection in the United States.美国艰难梭菌感染的负担
N Engl J Med. 2015 Feb 26;372(9):825-34. doi: 10.1056/NEJMoa1408913.
7
Comorbidities, Exposure to Medications, and the Risk of Community-Acquired Clostridium difficile Infection: a systematic review and meta-analysis.共病、药物暴露与社区获得性艰难梭菌感染风险：一项系统评价和荟萃分析
Infect Control Hosp Epidemiol. 2015 Feb;36(2):132-41. doi: 10.1017/ice.2014.39.
8
Low incidence of Clostridium difficile infection (CDI) in patients treated with outpatient parenteral antimicrobial therapy (OPAT).门诊胃肠外抗菌治疗（OPAT）患者艰难梭菌感染（CDI）的低发生率。
Infect Control Hosp Epidemiol. 2015 Jan;36(1):110-2. doi: 10.1017/ice.2014.6.
9
Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis.抗生素与医院获得性艰难梭菌感染：系统评价和荟萃分析更新。
J Antimicrob Chemother. 2014 Apr;69(4):881-91. doi: 10.1093/jac/dkt477. Epub 2013 Dec 8.
10
Can we identify patients at high risk of recurrent Clostridium difficile infection?我们能否识别出复发性艰难梭菌感染的高危患者？
Clin Microbiol Infect. 2012 Dec;18 Suppl 6:21-7. doi: 10.1111/1469-0691.12046.
Zotero 插件